Vanda Pharmaceuticals Inc. (VNDA) Receives Consensus Rating of “Buy” from Brokerages
Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) has been assigned an average recommendation of “Buy” from the ten ratings firms that are covering the firm, MarketBeat.com reports. One research analyst has rated the stock with a hold recommendation, seven have given a buy recommendation and one has issued a strong buy recommendation on the company. The average 12 month price objective among analysts that have covered the stock in the last year is $21.63.
A number of equities analysts recently weighed in on VNDA shares. Piper Jaffray Companies boosted their price target on shares of Vanda Pharmaceuticals from $23.00 to $26.00 and gave the stock an “overweight” rating in a report on Thursday, September 14th. Oppenheimer Holdings, Inc. reaffirmed a “buy” rating and issued a $21.00 price objective on shares of Vanda Pharmaceuticals in a research report on Thursday, September 14th. Jefferies Group LLC reaffirmed a “buy” rating and issued a $21.00 price objective on shares of Vanda Pharmaceuticals in a research report on Tuesday, August 29th. Zacks Investment Research cut shares of Vanda Pharmaceuticals from a “hold” rating to a “strong sell” rating in a research note on Tuesday, July 18th. Finally, BidaskClub raised shares of Vanda Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Tuesday, August 22nd.
Several institutional investors have recently bought and sold shares of VNDA. Legal & General Group Plc raised its stake in shares of Vanda Pharmaceuticals by 37.4% during the 2nd quarter. Legal & General Group Plc now owns 11,105 shares of the biopharmaceutical company’s stock valued at $181,000 after purchasing an additional 3,022 shares during the period. Kopp Investment Advisors LLC bought a new position in shares of Vanda Pharmaceuticals in the second quarter valued at approximately $196,000. Virginia Retirement Systems ET AL bought a new position in shares of Vanda Pharmaceuticals in the first quarter valued at approximately $193,000. Dynamic Technology Lab Private Ltd bought a new position in shares of Vanda Pharmaceuticals in the first quarter valued at approximately $196,000. Finally, Voya Investment Management LLC boosted its position in shares of Vanda Pharmaceuticals by 29.7% in the second quarter. Voya Investment Management LLC now owns 20,118 shares of the biopharmaceutical company’s stock valued at $328,000 after acquiring an additional 4,605 shares during the period. 86.49% of the stock is owned by hedge funds and other institutional investors.
Shares of Vanda Pharmaceuticals (NASDAQ:VNDA) traded down 0.139% on Wednesday, reaching $17.975. 68,919 shares of the company were exchanged. The company’s 50 day moving average is $17.29 and its 200 day moving average is $15.51. The firm’s market capitalization is $806.32 million. Vanda Pharmaceuticals has a 12-month low of $12.70 and a 12-month high of $18.99.
Vanda Pharmaceuticals (NASDAQ:VNDA) last posted its quarterly earnings data on Wednesday, August 2nd. The biopharmaceutical company reported ($0.03) earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.21) by $0.18. Vanda Pharmaceuticals had a negative return on equity of 7.85% and a negative net margin of 6.54%. The business had revenue of $42.06 million for the quarter, compared to analysts’ expectations of $40.31 million. During the same quarter in the previous year, the firm earned $0.01 earnings per share. The business’s revenue was up 16.7% on a year-over-year basis. Analysts forecast that Vanda Pharmaceuticals will post ($0.42) earnings per share for the current year.
About Vanda Pharmaceuticals
Vanda Pharmaceuticals Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of therapies to address unmet medical needs. Its product portfolio includes HETLIOZ (tasimelteon), Fanapt (iloperidone), Tradipitant (VLY-686), Trichostatin A and AQW051. It offers HETLIOZ for the treatment of Non-24-Hour Sleep-Wake Disorder (Non-24).
Receive News & Stock Ratings for Vanda Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vanda Pharmaceuticals Inc. and related stocks with our FREE daily email newsletter.